Sectors
DFTX
Mind Medicine (MindMed) Inc.
43.96
1 x 43.95
2 x 43.99
bid
ask
-
1.12
2.48%
01:33 PM
timesize
| Ytd | 185.83% | |
| 1y | 185.83% |
43.60
day range
44.99
12.88
52 week range
49.20
| Open | 44.02 | Prev Close | 45.08 | Low | 43.60 | High | 44.99 | Mkt Cap | 4.92B |
| Vol | 436.94K | Avg Vol | 4.53M | EPS | N/A | P/E | N/A | Forward P/E | -32.07 |
| Beta | 2.20 | Short Ratio | 5.00 | Inst. Own | 66.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 14.26 | 200-d Avg | 14.26 | 1yr Est | 57.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-07-30 | 2026-06 | -0.55 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | -0.47 | -0.71 | -0.24 | -51.06% |
| 2026-02-26 | 2025-12 | -0.48 | -0.51 | -0.03 | -5.44% |
| 2025-11-06 | 2025-09 | -0.52 | -0.78 | -0.26 | -50.00% |
| 2025-07-31 | 2025-06 | -0.38 | -0.5 | -0.12 | -31.58% |
| 2025-05-08 | 2025-03 | -0.36 | -0.35 | 0.01 | 2.78% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-08 | Stifel | Upgrade | Buy | Buy |
| 2026-06-30 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-06-24 | Jones Trading | Upgrade | Buy | Buy |
| 2026-06-23 | Baird | Upgrade | Outperform | Outperform |
| 2026-06-23 | Needham | Upgrade | Buy | Buy |
| 2026-06-22 | Leerink Partners | Upgrade | Outperform | Outperform |
Profile
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-24 | BARROW ROBERT B | Chief Executive Officer | 1.10M | Sale |
| 2026-06-10 | BRUHN SUZANNE LOUISE | Director | 24.29K | Stock Award(Grant) |
| 2026-06-10 | CRYSTAL ROGER | Director | 24.29K | Stock Award(Grant) |
| 2026-06-10 | GRYSKA DAVID W | Director | 19.90K | Stock Award(Grant) |
| 2024-08-20 | HALPERIN WERNLI MIRIAM | Officer | 202.41K | Conversion of Exercise of derivative security |
| 2026-06-24 | KARLIN DANIEL ROLLINGS | Officer | 503.28K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | BlackRock Inc | 8.48M | 0.00 | 6.39% |
| 2026-03-30 | Driehaus Capital Management LLC | 5.91M | 0.00 | 4.45% |
| 2026-03-30 | venBio Select Advisor LLC | 5.00M | 0.00 | 3.77% |
| 2026-03-30 | HHG PLC | 3.56M | 0.00 | 2.68% |
| 2026-03-30 | Deep Track Capital, LP | 3.00M | 0.00 | 2.26% |
| 2025-12-30 | Vanguard Group Inc | 2.59M | 0.00 | 1.95% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | iShares Russell 2000 ETF | 3.41M | 0.00 | 2.57% |
| 2026-06-29 | Vanguard Institutional Extnd Mkt Idx Tr | 1.49M | 0.00 | 1.12% |
| 2026-06-29 | iShares Russell 2000 Growth ETF | 1.22M | 0.00 | 0.92% |
| 2026-06-29 | T. Rowe Price New Horizons | 1.14M | 0.00 | 0.86% |
| 2026-04-29 | Fidelity Small Cap Index | 974.03K | 0.00 | 0.73% |
| 2025-12-30 | Candriam Eqs L Biotech C USD Cap | 971.22K | 0.00 | 0.73% |